AR052041A1 - Inmunoconjugados de anti - integrina, metodos y usos - Google Patents
Inmunoconjugados de anti - integrina, metodos y usosInfo
- Publication number
- AR052041A1 AR052041A1 ARP050105122A ARP050105122A AR052041A1 AR 052041 A1 AR052041 A1 AR 052041A1 AR P050105122 A ARP050105122 A AR P050105122A AR P050105122 A ARP050105122 A AR P050105122A AR 052041 A1 AR052041 A1 AR 052041A1
- Authority
- AR
- Argentina
- Prior art keywords
- conjugates
- composition
- therapy
- package
- diseases
- Prior art date
Links
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 108010040765 Integrin alphaV Proteins 0.000 abstract 1
- 206010029113 Neovascularisation Diseases 0.000 abstract 1
- 229940123237 Taxane Drugs 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 229940127093 camptothecin Drugs 0.000 abstract 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 abstract 1
- 230000012292 cell migration Effects 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 abstract 1
- 229960004679 doxorubicin Drugs 0.000 abstract 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 abstract 1
- 239000004744 fabric Substances 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 229940127073 nucleoside analogue Drugs 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 abstract 1
- 229960001237 podophyllotoxin Drugs 0.000 abstract 1
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 abstract 1
- 150000003230 pyrimidines Chemical class 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 238000011277 treatment modality Methods 0.000 abstract 1
- 239000003981 vehicle Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Cell Biology (AREA)
- Cardiology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Conjugados de anticuerpos específicos anti-integrina con compuestos citotoxicos, la síntesis, seleccion, y el uso de dichos conjugados para su uso en terapia del cáncer u otras enfermedades mediadas por proliferacion celular, migracion celular, o inflamacion y cuya patología involucra la angiogénesis o neovascularizacion de nuevos tejidos. Además, la presente se refiere a terapia de combinacion de dichas enfermedades donde el tratamiento comprende el uso de dichos conjugados en combinacion con una o más de otras modalidades de tratamiento, pero sin limitacion: quimioterapia, cirugía o terapia de radiacion. Los conjugados preferidos contienen compuestos maitansinoides unidos al anticuerpo mediante un enlace disulfuro, y los agentes quimioterapéuticos preferidos son doxorubicina, un taxano, una camptotecina, una podofilotoxina, un análogo nucleosídico, o un análogo de pirimidina. Reivindicacion 21: Una composicion farmacéutica que comprende un conjugado de acuerdo con cualquiera de las reivindicaciones 1 a 17 y un vehículo, diluyente o excipiente aceptable para uso farmacéutico. Reivindicacion 23: Un artículo de fabricacion que comprende la composicion del conjugado de cualquiera de las reivindicaciones 1 a 17 y un envase, y además comprende un prospecto del envase o rotulo que indica que la composicion puede usarse para tratar una enfermedad caracterizada por células que expresan la subunidad alfaV de integrina.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63444504P | 2004-12-09 | 2004-12-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR052041A1 true AR052041A1 (es) | 2007-02-28 |
Family
ID=36578407
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050105122A AR052041A1 (es) | 2004-12-09 | 2005-12-07 | Inmunoconjugados de anti - integrina, metodos y usos |
Country Status (25)
Country | Link |
---|---|
US (2) | US8603483B2 (es) |
EP (1) | EP1819359B1 (es) |
JP (1) | JP5421532B2 (es) |
KR (1) | KR101281501B1 (es) |
CN (1) | CN101193916B (es) |
AR (1) | AR052041A1 (es) |
AU (1) | AU2005314392B2 (es) |
BR (1) | BRPI0515745A (es) |
CA (1) | CA2591148A1 (es) |
DK (1) | DK1819359T3 (es) |
EA (1) | EA013323B1 (es) |
ES (1) | ES2539126T3 (es) |
HK (1) | HK1107001A1 (es) |
HU (1) | HUE025449T2 (es) |
IL (1) | IL183695A0 (es) |
MX (1) | MX2007007011A (es) |
NO (1) | NO20073493L (es) |
NZ (1) | NZ555601A (es) |
PL (1) | PL1819359T3 (es) |
PT (1) | PT1819359E (es) |
SG (1) | SG158119A1 (es) |
TW (1) | TWI400087B (es) |
UA (1) | UA94388C2 (es) |
WO (1) | WO2006062779A2 (es) |
ZA (1) | ZA200705556B (es) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2325344B1 (es) * | 2004-11-02 | 2010-06-09 | Univ Madrid Autonoma | Inhibidores de angiogenesis multifuncionales y multivalentes. |
JP5421532B2 (ja) * | 2004-12-09 | 2014-02-19 | セントカー・インコーポレーテツド | 抗インテグリン免疫コンジュゲート、方法および使用 |
EP2216653A1 (en) | 2005-08-02 | 2010-08-11 | XBiotech, Inc | Diagnosis, treatment and prevention of vascular disorders using il-1alpha autoantibodies |
RS54156B1 (en) * | 2006-03-21 | 2015-12-31 | Genentech Inc. | COMBINED THERAPY INCLUDING ALFA5BETA1 ANTAGONISTS |
ES2746925T3 (es) * | 2006-08-03 | 2020-03-09 | Medimmune Ltd | Anticuerpos dirigidos hacia alfaVbeta6 y uso de los mismos |
WO2008042611A2 (en) * | 2006-09-29 | 2008-04-10 | Centocor, Inc. | Method of using il6 antagonists with mitoxantrone for prostate cancer |
US20090175784A1 (en) * | 2007-05-11 | 2009-07-09 | Joshua Goldstein | Anti-Alpha V Immunoliposome Composition, Methods, and Uses |
US20090196913A1 (en) * | 2007-05-11 | 2009-08-06 | Ken Shi Kun Huang | Anti-Alpha-V Immunoliposome Composition, Methods, and Uses |
JP2011501656A (ja) | 2007-09-26 | 2011-01-13 | ジェネンテック, インコーポレイテッド | 新規抗体 |
NO2281006T3 (es) | 2008-04-30 | 2017-12-30 | ||
ES2797126T3 (es) | 2008-05-30 | 2020-12-01 | Xbiotech Inc | Usos de anticuerpos IL-1 alfa |
CA2731384C (en) * | 2008-07-21 | 2015-03-10 | The Brigham And Women's Hospital, Inc. | Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides |
CN102209557A (zh) | 2008-09-12 | 2011-10-05 | 埃克斯生物科技公司 | 靶向病原性单核细胞 |
EP2356457B1 (en) * | 2008-10-13 | 2018-05-16 | Xeptagen SPA | Method for the preparation of immunoconjugates and use thereof |
AU2010229479B2 (en) | 2009-03-25 | 2013-03-28 | Genentech, Inc. | Novel anti-alpha5beta1 antibodies and uses thereof |
MX349210B (es) | 2009-06-03 | 2017-07-18 | Immunogen Inc | Métodos de conjugación. |
FR2947269B1 (fr) * | 2009-06-29 | 2013-01-18 | Sanofi Aventis | Nouveaux composes anticancereux |
CA2676946A1 (en) * | 2009-08-28 | 2011-02-28 | Lucie Peduto | Adam12 inhibitors and their use against inflammation-induced fibrosis |
KR20120080611A (ko) | 2009-10-06 | 2012-07-17 | 이뮤노젠 아이엔씨 | 효능 있는 접합체 및 친수성 링커 |
CN105001334A (zh) | 2010-02-10 | 2015-10-28 | 伊缪诺金公司 | Cd20抗体及其用途 |
WO2011162933A1 (en) * | 2010-06-04 | 2011-12-29 | Immunogen, Inc. | Anti-integrin immunoconjugate dosing regimens |
CN102946904A (zh) | 2010-06-18 | 2013-02-27 | 埃克斯生物科技公司 | 关节炎治疗 |
CN107281488B (zh) * | 2010-08-23 | 2021-02-09 | 詹森生物科技公司 | 对肿瘤疾病的治疗 |
PT2634194T (pt) * | 2010-10-29 | 2018-10-19 | Perseus Proteomics Inc | Anticorpos anti-cdh3 possuidores de elevada capacidade de internalização |
MY171008A (en) | 2011-03-29 | 2019-09-23 | Immunogen Inc | Preparation of maytansinoid antibody conjugates by a one-step process |
KR102272828B1 (ko) | 2011-03-29 | 2021-07-05 | 이뮤노젠 아이엔씨 | 일-단계 방법에 의한 메이탄시노이드 항체 접합체의 제조 |
US9724409B2 (en) | 2011-04-01 | 2017-08-08 | Xbiotech, Inc. | Treatment of inflammatory skin disease |
AR086363A1 (es) | 2011-04-21 | 2013-12-11 | Bayer Ip Gmbh | Conjugados de principio activo-ligante (adc) y el uso de los mismos |
BR112013028890A2 (pt) * | 2011-05-09 | 2017-01-31 | Univ Virginia Patent Foundation | composições e métodos para o tratamento de câncer |
CA2849710C (en) | 2011-09-23 | 2020-04-28 | Xbiotech Inc. | Cachexia treatment |
RU2623441C2 (ru) * | 2012-01-27 | 2017-06-26 | Ф.Хоффманн-Ля Рош Аг | Конъюгаты антагонистов интегрина для нацеленной доставки к клеткам, экспрессирующим альфа-v-бета-3 |
MX360141B (es) * | 2012-02-17 | 2018-10-24 | Seattle Genetics Inc | Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer. |
US9545441B2 (en) | 2012-09-18 | 2017-01-17 | Xbiotech, Inc. | Treatment of diabetes |
ES2716561T3 (es) | 2012-09-26 | 2019-06-13 | Immunogen Inc | Métodos mejorados para la acilación de maitansinol |
SG11201502429YA (en) | 2012-10-04 | 2015-04-29 | Immunogen Inc | Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates |
US9180203B2 (en) * | 2012-10-23 | 2015-11-10 | The Johns Hopkins University | Self-assembling drug amphiphiles and methods for synthesis and use |
CA2898239A1 (en) | 2013-01-23 | 2014-07-31 | Syddansk Universitet | Mfap4 binding antibodies blocking the interaction between mfap4 and integrin receptors |
EP2777714A1 (en) | 2013-03-15 | 2014-09-17 | NBE-Therapeutics LLC | Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme |
US10005838B2 (en) * | 2013-07-19 | 2018-06-26 | The Regents Of The University Of California | Milk fat globule epidermal growth factor 8 regulates fatty acid uptake |
US20160354482A1 (en) | 2013-08-26 | 2016-12-08 | Regeneron Pharmaceuticals, Inc. | Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses |
PE20160996A1 (es) | 2013-12-23 | 2016-11-09 | Bayer Pharma AG | Conjugados de farmacos anticuerpo (adcs) con inhibidores de ksp |
JP2017526682A (ja) * | 2014-09-02 | 2017-09-14 | イミュノジェン, インコーポレイテッド | 抗体薬物複合体組成物の製剤化方法 |
KR20170088905A (ko) | 2014-11-19 | 2017-08-02 | 이뮤노젠 아이엔씨 | 세포 결합 작용제-세포독성 작용제 접합체를 제조하기 위한 공정 |
AU2015358367B2 (en) | 2014-12-04 | 2020-07-02 | Celgene Corporation | Biomolecule conjugates |
KR102556153B1 (ko) | 2014-12-23 | 2023-07-14 | 엔비이-테라퓨틱스 아게 | 안트라사이클린 유도체를 포함하는 결합단백질 약물 접합체 |
WO2016207089A1 (de) | 2015-06-22 | 2016-12-29 | Bayer Pharma Aktiengesellschaft | Binder-wirkstoff-konjugate (adcs) und binder-prodrug-konjugate (apdcs) mit enzymatisch spaltbaren gruppen |
WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
WO2017136623A1 (en) | 2016-02-05 | 2017-08-10 | Immunogen, Inc. | Efficient process for preparing cell-binding agent-cytotoxic agent conjugates |
GB201602356D0 (en) * | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
CN116059390A (zh) | 2016-03-24 | 2023-05-05 | 拜耳制药股份公司 | 具有酶促可裂解基团的细胞毒性活性物质的前药 |
CN109310781B (zh) | 2016-06-15 | 2024-06-18 | 拜耳制药股份公司 | 具有ksp抑制剂和抗-cd123-抗体的特异性抗体-药物-缀合物(adc) |
US11433140B2 (en) | 2016-12-21 | 2022-09-06 | Bayer Pharma Aktiengesellschaft | Specific antibody drug conjugates (ADCs) having KSP inhibitors |
IL310558A (en) | 2016-12-21 | 2024-03-01 | Bayer Pharma AG | Drug-antibody conjugates with enzymatically cleavable groups |
US12059472B2 (en) | 2016-12-21 | 2024-08-13 | Bayer Aktiengesellschaft | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
SG11201907159SA (en) | 2017-02-16 | 2019-09-27 | Xbiotech Inc | Treatment of hidradenitis suppurativa |
US10639382B2 (en) | 2017-04-13 | 2020-05-05 | National Guard Health Affairs | Method for treating leukemia |
CN110869051A (zh) * | 2017-05-30 | 2020-03-06 | 小利兰·斯坦福大学托管委员会 | 对神经炎症性疾病的治疗 |
JP2020523319A (ja) * | 2017-06-07 | 2020-08-06 | シルバーバック セラピューティックス インコーポレイテッド | 免疫調節化合物の抗体コンジュゲートおよびその使用 |
US20200046737A1 (en) | 2018-08-09 | 2020-02-13 | Notable Labs, Inc. | Methods for treating cancer, and compositions therefor |
CR20220057A (es) | 2019-07-10 | 2022-07-19 | Cybrexa 3 Inc | Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos |
BR112022000337A2 (pt) | 2019-07-10 | 2022-04-12 | Cybrexa 2 Inc | Conjugados de peptídeos de citotoxinas como terapêuticos |
WO2024001669A1 (zh) * | 2022-06-27 | 2024-01-04 | 昱言科技(北京)有限公司 | 靶向itga2的抗体和包含此抗体的抗体药物缀合物 |
CN115350187B (zh) * | 2022-08-30 | 2023-08-29 | 中山大学 | 异丙托溴铵在抑制肺癌骨转移中的应用 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3896111A (en) | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
SE430062B (sv) | 1977-03-04 | 1983-10-17 | Pharmacia Fine Chemicals Ab | Kopplings- eller tioleringsreagens |
US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
CA2026147C (en) * | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
AU3737893A (en) * | 1992-03-05 | 1993-10-05 | Board Of Regents, The University Of Texas System | Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells |
US5965132A (en) * | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
JP3161490B2 (ja) | 1993-07-30 | 2001-04-25 | 松下電器産業株式会社 | 金型装置 |
US6160099A (en) | 1998-11-24 | 2000-12-12 | Jonak; Zdenka Ludmila | Anti-human αv β3 and αv β5 antibodies |
GB9909392D0 (en) * | 1999-04-24 | 1999-06-23 | Imp Cancer Res Tech | Treatment, imaging and diagnosis of disease |
EP2977063A1 (en) | 1999-06-25 | 2016-01-27 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
US7163681B2 (en) * | 2000-08-07 | 2007-01-16 | Centocor, Inc. | Anti-integrin antibodies, compositions, methods and uses |
US7288390B2 (en) * | 2000-08-07 | 2007-10-30 | Centocor, Inc. | Anti-dual integrin antibodies, compositions, methods and uses |
AR030612A1 (es) * | 2000-09-12 | 2003-08-27 | Smithkline Beecham Corp | Procedimiento e intermedios |
US20020197261A1 (en) * | 2001-04-26 | 2002-12-26 | Chun Li | Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use |
US20030103985A1 (en) * | 2001-05-18 | 2003-06-05 | Boehringer Ingelheim International Gmbh | Cytotoxic CD44 antibody immunoconjugates |
EP1258255A1 (en) | 2001-05-18 | 2002-11-20 | Boehringer Ingelheim International GmbH | Conjugates of an antibody to CD44 and a maytansinoid |
US6441163B1 (en) * | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
JP2005525423A (ja) | 2002-05-13 | 2005-08-25 | スミスクライン・ビーチャム・コーポレイション | メイタンシノールの調製方法 |
DE60336149D1 (de) | 2002-08-16 | 2011-04-07 | Immunogen Inc | Vernetzer mit hoher reaktivität und löslichkeit und ihre verwendung bei der herstellung von konjugaten für die gezielte abgabe von kleinmolekularen arzneimitteln |
US7374762B2 (en) * | 2003-05-14 | 2008-05-20 | Immunogen, Inc. | Drug conjugate composition |
ES2863498T3 (es) | 2003-05-20 | 2021-10-11 | Immunogen Inc | Agentes citotóxicos mejorados que comprenden nuevos maitansinoides |
US7276497B2 (en) * | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
JP5421532B2 (ja) * | 2004-12-09 | 2014-02-19 | セントカー・インコーポレーテツド | 抗インテグリン免疫コンジュゲート、方法および使用 |
-
2005
- 2005-11-30 JP JP2007545515A patent/JP5421532B2/ja not_active Expired - Fee Related
- 2005-11-30 SG SG200908161-3A patent/SG158119A1/en unknown
- 2005-11-30 CN CN2005800478135A patent/CN101193916B/zh not_active Expired - Fee Related
- 2005-11-30 CA CA002591148A patent/CA2591148A1/en not_active Abandoned
- 2005-11-30 AU AU2005314392A patent/AU2005314392B2/en not_active Ceased
- 2005-11-30 HU HUE05852484A patent/HUE025449T2/en unknown
- 2005-11-30 WO PCT/US2005/043250 patent/WO2006062779A2/en active Application Filing
- 2005-11-30 KR KR1020077015643A patent/KR101281501B1/ko not_active IP Right Cessation
- 2005-11-30 EA EA200701250A patent/EA013323B1/ru not_active IP Right Cessation
- 2005-11-30 NZ NZ555601A patent/NZ555601A/en not_active IP Right Cessation
- 2005-11-30 PL PL05852484T patent/PL1819359T3/pl unknown
- 2005-11-30 DK DK05852484T patent/DK1819359T3/en active
- 2005-11-30 PT PT58524844T patent/PT1819359E/pt unknown
- 2005-11-30 UA UAA200706239A patent/UA94388C2/ru unknown
- 2005-11-30 US US11/290,249 patent/US8603483B2/en not_active Expired - Fee Related
- 2005-11-30 ES ES05852484.4T patent/ES2539126T3/es active Active
- 2005-11-30 BR BRPI0515745-5A patent/BRPI0515745A/pt not_active IP Right Cessation
- 2005-11-30 EP EP05852484.4A patent/EP1819359B1/en active Active
- 2005-11-30 MX MX2007007011A patent/MX2007007011A/es active IP Right Grant
- 2005-12-07 AR ARP050105122A patent/AR052041A1/es not_active Application Discontinuation
- 2005-12-08 TW TW094143287A patent/TWI400087B/zh not_active IP Right Cessation
-
2007
- 2007-06-05 IL IL183695A patent/IL183695A0/en unknown
- 2007-07-06 NO NO20073493A patent/NO20073493L/no not_active Application Discontinuation
- 2007-07-06 ZA ZA200705556A patent/ZA200705556B/xx unknown
- 2007-11-15 HK HK07112495.8A patent/HK1107001A1/xx not_active IP Right Cessation
-
2013
- 2013-12-04 US US14/096,767 patent/US20140093523A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR052041A1 (es) | Inmunoconjugados de anti - integrina, metodos y usos | |
GT200500054A (es) | Conjugados de caliqueamicina | |
CL2008002852A1 (es) | Compuestos derivados de 7-fluoro-5-metil-2-(fenilamino)-6,7,8,9-tetrahidro-5h-pirimido[4,5-b][1,4]diazepin-6(7h)-ona; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de canceer, inflamacion, alopecia, enfermedades autoinmune, cardiovasculares, infecciosas, nefrologicas, neurodfegenerativas, cutaneas y oseas. | |
UY29244A1 (es) | Combinaciones medicas | |
AR059982A1 (es) | Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano | |
CL2021000901A1 (es) | Enlazadores de conjugación que contienen el grupo 2,3-diaminosuccinilo | |
DK1594542T3 (da) | Anti-CD70 antistof-lægemiddelkonjugater og deres anvendelse ved behandling af cancer | |
BR112016004242A8 (pt) | Métodos para conjugação sítio-específica de anticorpos e composições | |
MX2023001163A (es) | Conjugado de farmaco anticuerpo anti-cd79b, metodo de preparacion y uso farmaceutico del mismo. | |
UY27943A1 (es) | Composiciones y mctodos para tratar el crncer usando inmunoconjugados de anticuerpo para cd44 citotnxicos y agentes quimioterapcuticos | |
PA8791701A1 (es) | Imidazopiridinonas | |
AR085334A1 (es) | Inmunoterapia mejorada, composicion farmaceutica, kit | |
BR122019027966B8 (pt) | conjugado monomérico de derivado de caliqueamicina/anti-corpo anti-cd22 e uso dos mesmos | |
AR063086A1 (es) | Anticuerpos humanos que se unen a cxcr4 y usos de los mismos | |
DE602006012667D1 (de) | Fusionsprotein von antikörper l19 gegen fibronectin ed-b und interleukin 12 | |
AR057239A1 (es) | Inmunoglobulinas | |
PA8594801A1 (es) | Formulaciones farmaceuticas liquidas de palanosetron | |
AR066690A1 (es) | Agentes terapeuticos para canceres resistentes a agentes quimioterapeuticos que incluyen como ingrediente activo un anticuerpo que reconoce hla de clase i y sus usos | |
CO2018000414A2 (es) | Inmunoconjugados de il22 | |
CO2020006443A2 (es) | Métodos y composiciones para la dosificación de células t con receptor de antígeno quimérico alogénicas | |
JP2006517970A5 (es) | ||
CO2023004110A2 (es) | Anticuerpos anti-fgfr2 y métodos para usarlos | |
ES2376564B1 (es) | Utilización de anticuerpos contra los receptores nk1, nk2 y/o nk3, para producir apoptosis en las células tumorales y modificar el estroma, la inmunidad y la vascularización intra y peritumorales, como tratamiento del cáncer. | |
MX2022002555A (es) | Conjugados de farmaco de anticuerpo de union a receptor de tipo ii de la hormona anti-mulleriana humana (amhrii) y uso de los mismos en el tratamiento de canceres. | |
Goel et al. | Natural products as a source of cytotoxic warheads in antibody-drug conjugates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |